Tesamorelin
GHRH analog. Tesamorelin is FDA approved (Egrifta); research-chemical versions are not the approved drug.
Key facts
- Class
- GHRH analog
- Also called
- tesa, Egrifta
- Vial sizes sold
- 2 mg, 5 mg, 10 mg, 20 mg
- Community-reported sizes
- Half-life
- 11 minutes
- subcutaneous (EGRIFTA WR 1.28 mg), in people · FDA label (Egrifta WR)
- FDA status
- Approved (Egrifta)
- Approved
- WADA
- Prohibited (S2.2.4)
- In and out of competition
Tesamorelin guides
Explained
Questions
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Weight loss | 34 | 0 | 10 | Human RCT evidence, 4 of 4eNeurologicalSci 2026, PMID 42382101 |
| Muscle growth | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Sleep | 1 | 0 | 1 | Human RCT evidence, 4 of 4eNeurologicalSci 2026, PMID 42382101 |
| Heart health | 13 | 0 | 6 | Human RCT evidence, 4 of 4Clinical infectious diseases 2012, PMID 22495074 |
| Diabetes | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Liver | 14 | 1 | 1 | Human RCT evidence, 4 of 4The lancet. HIV 2019, PMID 31611038 |
| Joint pain | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
A growth hormone-releasing factor analog with one approved use
The US label limits use to reducing excess abdominal fat in HIV-infected adults with lipodystrophy.[6]
The label states it is not indicated for weight loss management because it has a weight neutral effect.[6]
The same drug, different fates by country
FDA lists the drug as a prescription powder; the cached record shows an original approval date of 20101110.[2]
Health Canada shows the brand as Cancelled Post Market.[11]
The EMA export marks the central application as withdrawn.[12]
WADA's list names tesamorelin among GHRH analogues, whether or not it is an approved medicine.[1]
Strongest finding and open question
A phase 3 trial in HIV lipodystrophy found visceral fat down 15.2% on tesamorelin and up 5.0% on placebo.[13]
In the second phase 3 trial, early improvements in visceral fat were rapidly lost in people switched from tesamorelin to placebo.[14]
Outside HIV the evidence is thin: a small placebo-controlled pilot of low-dose tesamorelin in adults with cognition from normal to mildly impaired, which also measured fatigue and sleep, found no significant changes.[4]
Compared with
Common stacks
Tesamorelin is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.
Common questions
Is Tesamorelin FDA approved?
Tesamorelin is FDA approved (Egrifta). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
Is Tesamorelin banned in sport?
Yes. Prohibited by WADA (S2.2.4), so it is prohibited at all times for tested athletes.
How much water goes in a 10 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What does tesamorelin do?
The label calls it a growth hormone-releasing factor analog, indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.[6]
How does tesamorelin work?
The label says it induces the release of endogenous growth hormone.[6]
What is the half-life of tesamorelin?
The Egrifta WR label reports a half-life of 11 minutes after subcutaneous dosing.[6]
Is tesamorelin approved for women?
The label lists pregnancy among its contraindications.[6]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: Approved by FDA as Egrifta (original approval 10 Nov 2010), Theratechnologies, for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 4The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 5Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026
- 6EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) (104 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (tesamorelin[tiab] OR TH9507[tiab]) AND (pharmacokinetic*[tiab] OR half-life[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 10PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (36 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 11Health Canada Drug Product Database search: ingredient name "tesamorelin"Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
- 12ema.europa.eu pageEuropean Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
- 13Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 14Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999) · 2010PMID 20101189Accessed 2 Oct 2026
Found an error? Report a correction.